IDEXX Laboratories Non-GAAP EPS of $2.70 beats by $0.23, revenue of $943.63M beats by $9.58M
IDEXX Laboratories press release (NASDAQ:IDXX): Q2 Non-GAAP EPS of $2.70  beats by $0.23.
Revenue of $943.63M (+9.7% Y/Y)  beats by $9.58M.
Records second quarter revenue growth of 10% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 12% organic
Updates 2023 revenue guidance to $3,660 million - $3,715 million ($3.67B consensus), reflecting 8.5% - 10% growth as reported and organically, driven by projected CAG Diagnostics recurring revenue growth of 10% - 11% as reported and organically
Increases 2023 EPS outlook to $9.64 - $9.90 ($9.67 consensus), a year-over-year increase of 20% - 23% as reported and 24% - 27% on a comparable basis, including ~12% combined EPS growth benefit from a customer contract resolution payment in Q1 2023 and lapping of discrete 2022 R&D investments